NEU is a biopharmaceutical company developing therapies for brain injury and neurodevelopmental and neurodegenerative disorders. In July, the company made an extremely exciting agreement with North American partner Acadia Pharmaceuticals (ACAD US), which saw the stock more than double over just a few weeks. We are conscious that the “easy money” post the announcement is behind the stock, and in this volatile and highly uncertain space, the risk/reward is clearly lower than in 2022, but after the recent 30% correction, the picture has improved somewhat.
- We like NEU around current levels, but on the whole, historically, we have not made money in Biotech and it’s unlikely we will venture into this volatile space.
MM is cautiously bullish toward NEU under $11, noting this is a very high risk space
Add To Hit List
